- Statistical Significance Achieved for Primary Endpoint of Ocular Itching at All Prespecified Timepoints (p
Aldeyra Therapeutics Achieves Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 INVIGORATE Clinical Trial of Reproxalap in Allergic Conjunctivitis
Aldeyra Therapeutics, Inc. on 6ix
In the deck
Story so far
- Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 INVIGORATE Clinical Trial
- Aldeyra Announces First Patient Enrolled in the Phase 3 TRANQUILITY Trial of Reproxalap for the Treatment of Dry Eye Disease
- Aldeyra Therapeutics Announces First Patient Enrolled in the Phase 3 INVIGORATE Trial in Allergic Conjunctivitis
Earlier from Aldeyra Therapeutics
- Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 INVIGORATE Clinical Trial
- Aldeyra Therapeutics Reports Full-Year 2020 Financial Results and Recent Business Highlights
- Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Full-Year 2020 Financial Results and Discuss Recent Business Highlights
- Aldeyra Therapeutics Announces Phase 3 TRANQUILITY Dry Eye Disease Trial Design
- Aldeyra Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Later from Aldeyra Therapeutics
- Aldeyra Therapeutics, Inc. Announces Pricing of $125 Million Public Offering of Common Stock
- Aldeyra Therapeutics Schedules Webcast and Conference Call to Report First-Quarter 2021 Financial Results and Discuss Recent Business Highlights
- Aldeyra Therapeutics Reports First-Quarter 2021 Financial Results and Recent Business Highlights
- Aldeyra Therapeutics Joins the Russell 2000® and Russell 3000® Indexes
- Aldeyra Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for ADX-2191 to Treat Primary Vitreoretinal Lymphoma
Follow Aldeyra Therapeutics into a list and get an email when it puts out news.
Follow Aldeyra Therapeutics